PMID- 26330243
OWN - NLM
STAT- MEDLINE
DCOM- 20160211
LR  - 20220129
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 126
IP  - 17
DP  - 2015 Oct 22
TI  - Prediction of high- and low-risk multiple myeloma based on gene expression and 
      the International Staging System.
PG  - 1996-2004
LID - 10.1182/blood-2015-05-644039 [doi]
AB  - Patients with multiple myeloma have variable survival and require reliable 
      prognostic and predictive scoring systems. Currently, clinical and biological 
      risk markers are used independently. Here, International Staging System (ISS), 
      fluorescence in situ hybridization (FISH) markers, and gene expression (GEP) 
      classifiers were combined to identify novel risk classifications in a 
      discovery/validation setting. We used the datasets of the Dutch-Belgium 
      Hemato-Oncology Group and German-speaking Myeloma Multicenter Group 
      (HO65/GMMG-HD4), University of Arkansas for Medical Sciences-TT2 (UAMS-TT2), 
      UAMS-TT3, Medical Research Council-IX, Assessment of Proteasome Inhibition for 
      Extending Remissions, and Intergroupe Francophone du Myelome (IFM-G) (total 
      number of patients: 4750). Twenty risk markers were evaluated, including t(4;14) 
      and deletion of 17p (FISH), EMC92, and UAMS70 (GEP classifiers), and ISS. The 
      novel risk classifications demonstrated that ISS is a valuable partner to GEP 
      classifiers and FISH. Ranking all novel and existing risk classifications showed 
      that the EMC92-ISS combination is the strongest predictor for overall survival, 
      resulting in a 4-group risk classification. The median survival was 24 months for 
      the highest risk group, 47 and 61 months for the intermediate risk groups, and 
      the median was not reached after 96 months for the lowest risk group. The 
      EMC92-ISS classification is a novel prognostic tool, based on biological and 
      clinical parameters, which is superior to current markers and offers a robust, 
      clinically relevant 4-group model.
CI  - (c) 2015 by The American Society of Hematology.
FAU - Kuiper, Rowan
AU  - Kuiper R
AD  - Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The 
      Netherlands;
FAU - van Duin, Mark
AU  - van Duin M
AD  - Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The 
      Netherlands;
FAU - van Vliet, Martin H
AU  - van Vliet MH
AD  - SkylineDx, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands;
FAU - Broijl, Annemiek
AU  - Broijl A
AD  - Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The 
      Netherlands;
FAU - van der Holt, Bronno
AU  - van der Holt B
AD  - Hemato-Oncologie voor Volwassenen Nederland Data Center, Erasmus Medical Center 
      Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands;
FAU - El Jarari, Laila
AU  - El Jarari L
AD  - Hemato-Oncologie voor Volwassenen Nederland Data Center, Erasmus Medical Center 
      Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands;
FAU - van Beers, Erik H
AU  - van Beers EH
AD  - SkylineDx, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands;
FAU - Mulligan, George
AU  - Mulligan G
AD  - Millennium Pharmaceuticals, Cambridge, MA;
FAU - Avet-Loiseau, Herve
AU  - Avet-Loiseau H
AD  - Unite de Genomique du Myelome, Centre Hospitalier Universitaire Rangueil, 
      Toulouse, France;
FAU - Gregory, Walter M
AU  - Gregory WM
AD  - Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Royal Marsden Hospital, London, United Kingdom;
FAU - Goldschmidt, Hartmut
AU  - Goldschmidt H
AD  - University of Heidelberg, Heidelberg, Germany; and.
FAU - Lokhorst, Henk M
AU  - Lokhorst HM
AD  - Department of Hematology, University Medical Center Utrecht, Utrecht, The 
      Netherlands.
FAU - Sonneveld, Pieter
AU  - Sonneveld P
AD  - Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The 
      Netherlands;
LA  - eng
GR  - MR/L01629X/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150901
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*genetics
MH  - *Chromosome Aberrations
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Expression Profiling
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - International Agencies
MH  - Male
MH  - Middle Aged
MH  - Models, Theoretical
MH  - Multiple Myeloma/*genetics/mortality/*pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Risk Factors
MH  - Survival Rate
PMC - PMC4616233
EDAT- 2015/09/04 06:00
MHDA- 2016/02/13 06:00
PMCR- 2015/10/22
CRDT- 2015/09/03 06:00
PHST- 2015/05/03 00:00 [received]
PHST- 2015/08/19 00:00 [accepted]
PHST- 2015/09/03 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
PHST- 2015/10/22 00:00 [pmc-release]
AID - S0006-4971(20)30798-9 [pii]
AID - 2015/644039 [pii]
AID - 10.1182/blood-2015-05-644039 [doi]
PST - ppublish
SO  - Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 
      2015 Sep 1.